Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anti-Kickback Reforms Urged To Support Outcomes-Based System

Executive Summary

AdvaMed wants more safe harbors around product warranties and rebates, while the Healthcare Leadership Council is asking for protections for health records software and manufacturer giveaways.

You may also be interested in...



Full Steam Ahead On Medtech Value-Based Business Models

Federal health-care policy in the US, at least, is potentially in for a major transition, but that is not having much of an impact on the fundamental business models of medtech firms and their ever-accelerating focus on value-based and risk-sharing business models. Emphasis on value strategies was a significant medtech theme at this year's JP Morgan Healthcare Conference bonanza.

HHS Inspector General Rule Expands Safe Harbors For Beneficiary Remuneration

The final rule protects retailer coupons, free products for the financially needy, and remuneration that clearly promotes access to care.

Take Compensation Pieces Out Of Stark Law, Legal Experts Tell Senators

Legal experts and a hospital CEO agreed at a Senate Finance Committee hearing that getting rid of the compensation components of the Stark Law barring physician self-referrals – while keeping in the ownership restrictions – may be the best way to protect patients from overuse of medical services while promoting value-based payment systems.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel